As the recent General Manager of BeiGene Canada, Brenders established and lead the Canadian affiliate operations by recruiting and developing a cross-functional team to launch new oncology therapies in Canada.

He took the affiliate from start‑up to $100 million in sales in a highly competitive market in just over three years, and achieved the status of #1 worldwide affiliate in terms of product per capita demand. Under his leadership, BeiGene Canada was recognized as a Great Place to Work®, which speaks to his expertise in creating a supportive workplace culture that is vital to the success of the company and its employees. 

Brenders is celebrated not only for his professional accomplishments but also for his reputation as a collaborator and problem-solver. He has been inducted into the Canadian Healthcare Marketing Hall of Fame, an honour that underscores his contributions to healthcare marketing and his ability to inspire others in the field.

Known for his expertise in strategic planning, organizational transformation, and market access, Brenders has consistently driven impactful initiatives launching over 20 products in Canada across diverse therapeutic areas, including oncology, neurology, rare diseases, nephrology, and hematology.

His reputation extends beyond technical expertise; Brenders is regarded as a thought leader who advocates for systemic improvements in healthcare access. He has spoken out on critical issues such as the inefficiencies of Canada’s healthcare system in adopting new therapies and the complexities surrounding national pharmacare debates. Brenders emphasizes the importance of aligning stakeholders—clinicians, advocacy groups, and policymakers—to create meaningful solutions tailored to patient needs.

In addition to his corporate roles, Brenders actively contributes to the broader life sciences community through board memberships and advisory positions. He has served on the Boards of Research Canada, VIDO-Intervac, and The Cameron Institute. He has also served as a member of the advisory board of the Montreal Neurological Institute’s clinical research unit, the Life Sciences Advisory Group of Global Affairs Canada, the federal Department of Foreign Affairs Trade and Development’s Life Sciences Advisory Group, the Advisory Board for the National Research Council’s (NRC) Institute for Marine Biosciences and the NRC’s Institute for Nutrisciences and Health, the Canadian Agri-Food Policy Institute Advisory Board, and was an Industry Advisor for the Atlantic Canada Opportunity Agency’s Atlantic Innovation Fund Committees for Aquaculture and Biotechnology Sector and Health and Medical Sector.

Peter received his MBA in Health Services Management from McMaster University. Prior to his brief work in basic research at the Robarts Research Institute, he received his Honours BSc in Pharmacology and Toxicology from the University of Western Ontario. Peter also has completed executive education programs at the Stanford University Graduate School of Business, Harvard Business School, McGill University and Queen’s University.